Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that
carry blood from the heart to the lungs. PAH occurs when the openings in the blood vessels of
the lungs get smaller and smaller. These smaller openings can be caused by the following:
- The walls of the arteries tightening
- The walls of the arteries becoming stiff and narrow from an overgrowth of cells The
increased pressure in the pulmonary arteries strains the right side of the heart and it
begins to fail, causing difficulty breathing and other symptoms. As PAH progresses,
symptoms get worse.
There is no...
Researchers are looking for a better way to treat people who have pulmonary hypertension (PH)
due to left heart disease. PH due to left heart disease is a condition of high blood pressure
in the vessels of the lungs caused by diseases in the left side of the heart.
The study treatment, BAY2701250 is under development and will be tested in humans for the
first time in this study. Once it is approved, it may help treat people with PH due to left
The participants of this study will be healthy and will have no benefit from the
administration of BAY2701250. However, the study will provide important information for the
Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 3000 US live births,
similar to the incidence seen within the Utah Birth Defects cohort. The diaphragmatic defect
compromises lung growth and alters pulmonary vascular development. This is reflected
postnatally as respiratory failure, pulmonary hypertension (PH) and overall cardiopulmonary
dysfunction, particularly post-repair. Currently, optimal management of post-repair PH
remains poorly investigated. Sildenafil citrate is a highly selective phosphodiesterase-5
inhibitor that increases cGMP levels, leading to smooth muscle relaxation and an
The purpose of this study is to determine whether a regimen of high-dose immunoablative
therapy will demonstrate safety that is consistent or improved with other published regimens
in SSc patients, while maintaining a treatment effect.
Balloon pulmonary angioplasty (BPA) emerged as a potential therapeutic option for
non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH).
The aim of this study was to evaluate the safety and efficacy of BPA in patients disqualified
from surgery or suffered from persistent CTEPH despite pulmonary endarterectomy.
This is a interventional study analyzing the benefits and the risk of BPA. Clinical
evaluation, including: functional capacity, 6-minutes walking test, haemodynamics,
biomarkers, cardiopulmonary exercise test, echocardiography, electrocardiography and QoL
assessment with Short Form 36 (SF36)...
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the
indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension
(CTE-PHT) prevention, the frequent prescription (50 to 90% of patients) contrasts with their
low level of proof in the PHT. Last but not least, anticoagulants are known to be the
principal cause of iatrogenic hospitalization (major bleeding).
In this study, patients are all followed during one year, to determine the annual frequency
of major bleedings (according to the International Society on Thrombosis and Haemostasis
(ISTH) international definition). Each...
This observational study is being done to understand why people with scleroderma can develop
pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a
weak heart muscle (heart failure). The study will also help the investigators understand why
people with PAH from an unknown cause (called idiopathic PAH, or IPAH) can also develop a
weakened heart muscle. The response of the right side of the heart or right ventricle (RV) to
standard PAH therapy in scleroderma-associated PAH and in IPAH will be assessed. Blood and
tissue samples will be collected from research participants during participants' normal
Pulmonary Arterial Hypertension is characterized by a progressive increase in pulmonary
vascular resistance inducing shortness of breath and exercise intolerance. We aim to
correlate cardiac function (evaluated at rest by right heart catheterism and RMN) to exercise
capacity (evaluated by endurance time at 75% of maximal workout), in prevalent patients with
pulmonary arterial hypertension, and their evolution at three and twelve months.
Radiotherapy improves locoregional control and survival of thoracic tumour patients. However,
the associated exposure of normal tissues, often leads to side effects and possibly even
reduces survival. Indeed, there is growing evidence that overall survival after radiotherapy
for lung and oesophageal cancer is related to the radiation dose to heart and lungs. This
suggests that thoracic radiotherapy causes mortality, which is currently not recognized as
radiation-induced toxicity. So the question arises how to explain this treatment-related
Interestingly, Ghobadi et al demonstrated in rats that thoracic irradiation can...
The Change Database is a prospective, observational multi-center disease registry, which will
collect data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) in China.
The registry will run for approximately 5 years. It aims to illustrate the epidemiology,
management and longterm outcomes of CTEPH.